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Abstract 
Purpose: The epidermal growth factor receptor (EGFR) family member HER3 is 
overexpressed in diverse human cancers and has been associated with poor 
prognosis in breast-, lung- and ovarian cancer. However, the relevance of HER3 with 
regard to its prognostic significance and function in primary melanoma and 
metastases remains largely elusive.  
Experimental Design: HER3 protein expression was analyzed 
immunohistochemically using tissue micro arrays of 130 primary melanoma and 87 
metastases relative to established clinical parameters. The possibility of an influence 
of HER3 on melanoma cell proliferation, migration, invasion and chemotherapy-
induced apoptosis was studied in human melanoma cell lines.  
Results: We demonstrate that HER3 is frequently expressed in malignant melanoma 
and metastases at elevated levels. High HER3 expression may serve as a prognostic 
marker since it correlates with cell proliferation, tumor progression and reduced 
patient survival. Suppression of HER3 expression by RNAi reduces melanoma cell 
proliferation, migration and invasion in vitro. In addition, down-regulation of HER3 
synergistically enhances dacarbazine-induced apoptosis. Moreover, monoclonal 
antibodies specific for the extracellular portion of HER3 efficiently block heregulin-
induced proliferation, migration and invasion of melanoma cell lines. 
Conclusion: Our results provide novel insights into the role of HER3 in melanoma 
and point out new possibilities for therapeutic intervention. 
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Introduction 
Melanoma is a common type of skin cancer, which develops from the malignant 
transformation of melanocytes, and accounts for 80% of deaths arising from skin 
cancer (1). The underlying molecular mechanisms of melanocyte transformation 
have been studied extensively in the past (2, 3). However, to date no drugs are 
available that significantly prolong patient survival once melanoma progresses to the 
metastatic state (4). Thus, there is an urgent need for novel therapeutic agents and 
prognostic markers in the treatment of melanoma patients. 
The human EGF receptor (HER) family of receptor tyrosine kinases regulates a large 
variety of biological processes including cell proliferation, -migration, -invasion and -
survival (5). The family consists of four members: EGFR (HER1), HER2 (neu or 
ErbB2), HER3 (ErbB3) and HER4 (ErbB4). To date eleven ligands have been 
reported including epidermal growth factor (EGF), heparin-binding EGF-like growth 
factor (HB-EGF), transforming growth factor α (TGFα), amphiregulin (AR), epiregulin, 
betacellulin and the heregulins. These ligands bind directly to their cognate 
receptors, which leads to the formation of receptor homo- or heterodimers that trigger 
the activation of multiple signaling pathways (6). Dysregulation of members of the 
HER-family either by activating mutations, receptor overexpression or aberrant ligand 
release leads to the development of a variety of human tumors (7). HER3 is over 
expressed in breast-, ovarian- and lung cancer and this genetic feature has been 
correlated with poor prognosis (8 - 10). Upon activation by heregulins, HER3 
dimerizes with HER2 and EGFR to form potent oncogenic receptor heterodimers (11 
- 13). Within this complex, HER3 preferentially recruits PI3-kinase to its cytoplasmic 
docking sites thereby regulating cell proliferation and -survival (14, 15). So far it was 
assumed that HER3 is kinase-inactive due to apparently aberrant sequence 
characteristics in its kinase domain and that it requires heterodimerization with a 
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kinase-intact member of the HER-family in order to initiate signaling events (16). 
Consistent with this, it was shown that HER2 requires HER3 to drive breast tumor 
cell proliferation (17). However, recent findings of Htuhn van der Horst and coworkers 
showed that HER3 is able to phosphorylate Pyk2 which results in the activation of the 
MAPK pathway in human glioma cells (18). Furthermore, monoclonal antibodies 
specific for HER3 can inhibit the proliferation and migration of cancer cell lines (19). 
Interestingly, it was shown recently that cancer cells escape HER-family inhibitor 
therapy by up-regulation of HER3 signaling (20) and that HER3 inhibition abrogates 
HER2-driven tamoxifen resistance in breast cancer cells (21). Moreover, resistance 
to Gefitinib (Iressa) therapy, an EGFR small molecule inhibitor, was shown to be 
connected to HER3 signal activation (22). 
In this study we analyzed the expression and prognostic significance of HER3 in 
malignant melanoma. We show that HER3 is up-regulated in melanoma and that 
high HER3 levels correlate with proliferation, tumor progression and reduced overall 
patient survival. In addition, we demonstrate that HER3 regulates proliferation, 
migration, invasion and cell survival of human melanoma cell lines. Moreover, 
blocking HER3 activation with specific monoclonal antibodies substantially reduced 
the proliferation, migration and invasion of these cell lines in vitro. In summary, our 
findings support a prognostic relevance of HER3 in melanoma and validate this HER-
family member as a potential target for the development of novel cancer therapies.  
 
Material and Methods 
Melanoma Patients 
Formalin-fixed, paraffin embedded tissue of 130 primary cutaneous melanoma and 
87 metastases was immunohistochemically analyzed for HER3. The patient age 
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ranged from 19 to 90 years. Clinical follow-up was available in all of the patients 
(mean clinical follow up was 56 ± 25 months). There were 60 nodular (NMM), 42 
superficial spreading (SSM), 3 lentiginous (LMM), 9 acral lentiginous (ALM) and 16 
not otherwise specified (NOS) melanoma. All melanoma had a Breslow tumor 
thickness between 0.4 and 17 mm. 53 of 130 patients (41%) had metastases during 
follow up and 24 of 130 patients (18%) died. Matched tumor samples of primary 
melanoma and metastases were available for 20 patients. 54 of the 130 patients with 
primary cutaneous melanomas were previously reported in a sentinel lymph node 
study (23). Approval was obtained from a local Institutional Ethical Committee and 
written informed consent signed by all study participants. 
 
Tissue micro array construction and Immunohistochemistry 
A morphologically representative region of a paraffin “donor” blocks was chosen to 
prepare the melanoma tissue micro arrays. The representative region was taken with 
a core tissue biopsy (diameter: 0.6 mm; height: 3-4 mm) and precisely arrayed into a 
new “recipient” paraffin block using a customer built instrument (24). After the block 
construction was completed, 4.0 µm sections of the resulting tumor tissue micro array 
block were cut with a microtome and used for further analysis. 
HER3 and Ki-67 immunohistochemistry was performed using a Ventana Benchmark 
automated staining system (Ventana Medical Systems, Tucson, Arizona). For 
antigen retrieval, slides were heated with cell conditioner 1 (standard procedure). 
Endogenous biotin was blocked with the appropriate kit. Primary antibodies against 
HER3 (Santa Cruz, clone C-17, dilution 1:50) and Ki-67 proliferation antigen (clone 
MIB-1, dilution 1:20 were applied and revealed with the iVIEW DAB detection kit, 
yielding a brown reaction product. The signal was enhanced with the Ventana 
amplification kit. Slides were counterstained with hematoxylin prior to glass cover-
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slipping. The specificity of the staining was controlled by using iso-type antibody 
controls, secondary antibody controls or blocking peptides. The analysis of the tissue 
micro arrays was done using a Zeiss Axiovert 300 microscope.  
 
Evaluation of HER3 expression 
To determine the expression frequencies of HER3, a semi-quantitative scoring 
system was applied following the German Immunohistochemical scoring (GIS) 
system in which the final immuno-reactive score equaled the product of the 
percentage of positive cells times the average staining intensity. Percentage of 
positive cells was graded as follows: 0 = negative, 1 = up to 10% positive cells, 2 = 
11 to 50%, 3 = 51 to 80%, 4 = >80%. Staining intensity of 0 = negative, 1 = weakly 
positive, 2 = moderately positive, 3 = strongly positive (25 - 27). The extent of KI-67 
staining was recorded as the Ki-67 Labeling Index (number of marked nuclei per 100 
melanoma cells). All stainings were evaluated by two different investigators (M.R. 
and D.M.-P.). 
 
Statistical analysis 
The protein expression frequency for HER3 was analyzed by dividing the GIS score 
in three groups with GIS 1-4 = no/low, GIS 5-8 = moderate and GIS 9-12 = high 
expression. For statistical analysis, two groups were considered which were divided 
through GIS-dichotomization at the median (low: GIS ≤6 and high: GIS >6). 
Correlations between HER3 and Ki-67 were analyzed using Spearman’s rank 
correlation. The overall survival of melanoma patients was estimated by the Kaplan 
Meier method and differences between groups were assessed by the log-rank test. 
The overall survival was defined as the time of primary tumor diagnosis to the last 
follow-up visit or patient death. All p-values were calculated using the two-sided 
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Fisher’s exact Test or the paired Student’s T-Test and p-values < 0.05 were 
considered statistically significant. A multivariable Cox regression model was 
adjusted, testing the independent prognostic relevance of HER3 in melanoma 
patients. The following clinical variables were considered: age (≤ 60 years vs. > 60 
years), sex (male vs female), tumor thickness (≤ 2mm vs > 2mm) and metastases 
during follow up. The proportionality assumption for all variables was assessed with 
log-negative-log survival distribution functions. For the analysis of matched tumor-
metastases pairs, the GIS values of HER3 in primary melanoma and melanoma 
metastases were directly compared and analyzed. The statistical analysis was 
performed with the SPSS 12.0 software (SPSS Inc., Chicago IL). 
 
Cell culture and compounds 
Human Colo 829 melanoma cells were maintained in RPMI 1640 medium 
supplemented with 10% fetal calf serum (FCS), 1% L-glutamine, 1% 
penicillin/streptomycin, 1% non-essential amino acids, 1% sodium pyruvate, 1% 
sodium bicarbonate, 10mM hepes and 4,5g/l glucose. Human MM-358, Mel Gerlach 
and Mel Juso melanoma cells were maintained in RPMI 1640 medium supplemented 
with 10% FCS, 1% L-glutamine and 1% penicillin/streptomycin. Dacarbazine and 
propidium-iodide were purchased from SIGMA. Heregulin ß1 was purchased from 
R&D Systems and diluted in PBS prior to use.  
 
RNA interference 
HER3 siRNAs were obtained from AMBION. Two independent siRNAs were used in 
all experiments. Sequences for HER3 siRNAs were sense1 5’ 
GGCUAUGUCCUCGUGGCCAtt 3’, antisense1 5’ UGGCCACGAGGACAUAGCCtg 
3’ and sense2 5’ GGCAGUGUGUCCUGGGACUtt 3’, antisense2 5’ 
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AGUCCCAGGACACACUGCCtg 3’. The GL-2 siRNA (Dharmacon) was used as a 
negative control in all experiments. GL-2_sense 5’ CGUACGCGGAAUACUUCGAtt 
3’, GL-2_antisense 5’ UCGAAGUAUUCCGCGUACGtt 3’. Transfection of siRNAs 
was done using Oligofectamine (Invitrogen, CA) according to manufacturer’s 
recommendation.  
 
Antibodies, RT-PCR and Western Blot analysis 
Antibodies against p-HER3 (Tyr 1289), p85, p-AKT (Ser473), CyclinB1, p-ERK1/2, p-
mTOR (Ser2448) and p-Rb (Ser780) were all purchased from Cell Signaling 
(Beverly, MA). HRP-conjugated rabbit secondary antibodies were from BioRad. Anti-
Tubulin, anti-ß-actin and HRP-conjugated mouse secondary antibodies were from 
SIGMA. The anti-HER3 (clone 2F12) antibody was from Upstate and anti-HER3 (C-
17) for Immunohistochemistry as well as Akt 1/2 (H-136) were from Santa Cruz. Anti-
p27 was purchased from Abcam. Western blot analysis and Immunoprecipitaions 
were done as described previously (28). Total RNA was isolated using the RNeasy 
Mini Kit (Quiagen) and c-DNA was synthesized using the AMV Reverse 
Transcriptase (Roche) according to manufacturer’s recommendations. RT-PCR 
primers for HER3: HER3_fwd 5’ CTCCGCCCTCAGCCTACCAGTT 3’ and HER3_rev 
5’ TGCTCCGGCTTCTACACATTGACA 3’ (Tm=64°C) and for Tubulin: Tubulin_fwd; 
5’ AAGTGACAAGACCATTGGGGGAGG 3’ and Tubulin_rev 5’ 
GGGCATAGTTATTGGCAGCATC 3’ (Tm = 55°C). All PCR reactions were done in 
an Eppendorf thermocycler (Eppendorf). 
 
Proliferation Assay 
75000 or 250000 cells were seeded in 24 well or 6 cm plates and transfected with 
HER3 or GL-2 siRNAs using oligofectamine (Invitrogen). The cells were either grown 
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in the presence of medium containing 10% FCS or serum-starved in medium 
containing 1% FCS and stimulated with 100ng/ml heregulin ß1. The cell number was 
counted (Coulter counter, Beckton Dickinson) at the indicated time points. The data 
are shown as mean ± SDM. 
 
 Migration and Invasion Assay 
200.000 cells were seeded in 6 well plates and transfected with HER3 or GL-2 
siRNAs using oligofectamine (Invitrogen). The cells were serum-starved in medium 
containing 0,1% FCS for 24 hours and 25.000 cells were either seeded on to a 
membrane or on to a growth factor reduced matrigel coated membrane with 8 µM 
pores of a modified boyden chamber (Schubert and Weiss) containing 500µl serum-
free medium. 10% fetal calf serum served as chemo attractant. The cells were 
allowed to migrate or invade for 20 or 24 hours, respectively. Migrated or invaded 
cells were stained with crystal violet, washed in PBS and pictures were taken on a 
Zeiss Axiovert 300 microscope. For quantification cells in at least 10 random fields 
were counted. The values for control cells were set to 100% and results are shown 
relative to controls. The data are shown as mean ± SDM. 
 
HER3 blocking antibody – Proliferation, Migration and Invasion experiments 
The HER3 blocking antibody (cl. 105.5) was purchased from Upstate, NY. The 
second HER3 blocking antibody (cl. 2D1D12) was generated in the Department of 
Molecular Biology at the Max-Planck Institute of Biochemistry. The HER2 blocking 
antibody (cl. 4D5) used was the non-humanized form of trastuzumab. 
The proliferation assay was performed using a MTT-Assay. Briefly, 7500 cells were 
seeded in 48 well plates. The cells were serum-starved in medium containing 1% 
FCS for 24 hours, pre-incubated with either 10µg/ml HER3 blocking antibody (cl. 
 10
105.5) or an isotype control antibody for 1 hour and stimulated with 100ng/ml 
heregulin ß1. The cells were allowed to grow for 48 hours and at that time point, MTT 
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolimbromide; thizolyl blue, Sigma, 
Taufkirchen) was added to each well at a final concentration of 1mg/ml. The plates 
were incubated for 2 hours. The yellow MTT dye is reduced by mitochondrial 
dehydrogenase activity to a purple formazan, which was then solubilized (SDS, 2-
Butanol and HCl) and absorbance was measured at 570nm on a micro-plate reader.  
MDA-MB 468 breast cancer cells were already described to be inhibited by the anti-
HER3 antibody (cl. 105.5) (19) and served as a positive control. The data are shown 
as percent of inhibition relative to control cells. 
The migration and invasion assays were performed as described previously (19, 29). 
Briefly, 300.000 cells were seeded in 6 cm plates and serum-starved in medium 
containing 0,1% FCS for 24 hours. 200.000 cells per ml were incubated with 10µg/ml 
HER3 blocking antibody or an isotype control antibody for 1 hour and 50.000 cells 
were then seeded either on to a membrane or on to a growth factor reduced matrigel 
coated membrane with 8 µM pores of a modified boyden chamber (Schubert and 
Weiss) containing 500µl serum free medium. Conditioned NIH 3T3 medium 
containing 0.01% ascorbic acid and heregulin ß1 (100ng/ml) were used as a chemo 
attractant. The cells were allowed to migrate or invade for 20 or 24 hours, 
respectively. Migrated or invaded cells were stained by crystal violet, washed in PBS 
and analyzed using a Zeiss Axiovert 300 microscope. For quantification at least 10 
random fields were counted. The values for control cells were set to 100% and 
results are shown relative to controls. The data are presented as mean ± SDM.  
To asses the HER3 phosphorylation state, cells were serum-starved for 24 hours, 
incubated with 10µg/ml blocking antibody for 1 hour, stimulated with 50ng/ml 
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heregulin ß1 for 2 hours, lysed and subjected to Immunoprecipitations using a 
specific HER3 antibody.  
 
Apoptosis Assay (Propidium Iodide staining)  
200.000 cells were seeded into 6 well plates (Nunc) and transfected with HER3 or 
GL-2 siRNAs. Apoptosis was induced by adding either 10 or 20µM dacarbazine in 
DMSO to the medium. After 48 hours the supernatant of each reaction was collected 
and the cells were trypsinized. After centrifugation the cells were incubated for two 
hours in a propidium-iodide buffer (0.1% Na-Citrate, 0.1% Triton X-100, 20µM 
Propidium-Iodide) and thereafter subjected to flow cytometric analysis (Beckton-
Dickinson Biosciences). Apoptotic cells were identified as the sub G0/G1 peak and 
quantified using the Cell Quest Pro software (Beckton Dickinson). 
  
Results 
HER3 is frequently expressed in primary melanoma and metastases 
We investigated HER3 protein expression in 130 primary malignant melanoma and 
87 metastases using tissue micro arrays. HER3 immuno reactivity was accentuated 
at the cell membrane. In primary melanoma, no or low HER3 expression was found 
in 45 out of 130 cases (35%) (Fig. 1A). Strikingly, moderate to high HER3 expression 
levels were found in 85 of 130 cases (65%) (Fig. 1B and 1C). Furthermore, HER3 
was highly expressed in 35 of 87 melanoma metastases (40%) (Fig. 1D). Taken 
together, HER3 is frequently expressed in primary melanoma and metastases 
indicating that HER3 may contribute to melanoma development and progression (Fig. 
1E). Importantly, HER3 expression was undetectable in primary melanocytes (Fig. 
1F). Interestingly, moderate to high HER3 expression significantly correlated with 
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increased tumor cell proliferation (Ki-67 Labeling Index) in primary malignant 
melanoma (p=0,008; data not shown).  
 
HER3 expression in melanoma progression 
To investigate the relevance of HER3 expression in primary melanoma we analyzed 
the relationship between HER3 and clinical parameters. In addition, matched tumor 
samples of primary melanoma and metastases were studied in 20 patients. 
Remarkably, 10 of 20 (50%) patients showed an increase of HER3 expression in the 
metastases compared to the primary tumor. Six of 20 (30%) matched tumor samples 
showed a similar expression of HER3 and only 4 of 20 (20%) patients showed less 
HER3 expression in the metastases when compared to the primary tumor (Fig. 2A). 
These results show that in a majority of cases HER3 expression remains either 
stable or even increases during disease progression.  
Importantly, Kaplan-Meier analysis showed that HER3 expression was significantly 
associated with tumor specific survival (p=0,014) (Fig. 2B). In a multivariate analysis, 
an adjusted Cox regression model was developed for the assessment of the overall 
survival rate. The characteristics of the variables are shown in Table 1. The clinical 
variables used in the analysis were age, sex, metastases during progression, tumor 
thickness and HER3 expression (HER3 Immunohistochemistry score). In this model, 
metastases (p=0,000) and HER3 expression (p=0.041) were correlated with poor 
prognosis. The hazard ratio for death from melanoma concerning HER3 status was 
2.6 (95% Confidence Interval: 1,042-6,671); accordingly, in cases with high HER3 
expression, the probability of tumor-related death was almost three times higher than 
in cases with low HER3 staining. Because of the assumption of proportional hazards, 
the probability of melanoma-related death was consistently valid during the entire 
observation period. Notably, HER3 expression did not significantly correlate with any 
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other clinical parameters (e.g.: tumor thickness, ulceration) tested. Taken together, 
these results indicate that HER3 is a critical parameter for melanoma prognosis and 
progression. 
 
HER3 knock-down inhibits melanoma cell proliferation 
In order to further characterize the role of HER3 in melanoma, we down-regulated 
HER3 by specific siRNAs in Colo 829, MM-358, Mel Gerlach and Mel Juso human 
melanoma cell lines (Fig. 3A, Suppl.-Fig. 1A and 2A). Strikingly, depletion of HER3 
strongly inhibited proliferation in these cell lines (Fig. 3B, Suppl.-Fig. 1A and 2B). To 
further characterize the mechanism of the growth inhibition we analyzed proteins 
implicated in cell cycle control. As shown in Fig. 3B, HER3 knock-down led to 
increased p27 levels, reduced Cyclin B1 levels and decreased Rb phosphorylation 
suggesting that HER3 controls melanoma cell proliferation by interfering with key cell 
cycle regulators. In addition, HER3 knock-down strongly inhibited heregulin-induced 
cell proliferation (Fig. 3B and Suppl.-Fig. 1A). Importantly, HER3 predominantly 
signals via the PI3K-AKT pathway in the regulation of cell proliferation and -survival. 
Indeed, AKT activation was impaired in heregulin ß1 stimulated knock-down cell lines 
indicating that HER3 may signal via the PI3K-AKT pathway in melanoma cells (Fig. 
3C and Suppl.-Fig. 1B). In contrast, p-ERK and p-mTOR levels remained unchanged 
(Fig. 3C and Suppl.-Fig. 1B). Notably, HER2 protein levels were not altered in HER3 
down-regulated cells suggesting that the effects are specific for HER3 (Suppl.-Fig. 3). 
Our data demonstrate that HER3 appears to promote melanoma cell proliferation 
which most likely involves the modulation of key cell cycle regulators.   
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HER3 knock-down inhibits melanoma cell migration and invasion and 
sensitizes melanoma cells to dacarbazine-induced apoptosis 
Melanoma metastases frequently express high levels of HER3 (Fig. 1D and 1E). 
Given the association between HER3 expression and poor survival, one might 
hypothesize that HER3 plays a role in melanoma progression. Increased tumor cell 
migration and invasion are important prerequisites for metastasis. In order to address 
this question, we analyzed the migration and invasion of Colo 829, MM-358 and Mel 
Gerlach melanoma cells upon interference with HER3 expression. To exclude the 
possibility of measuring inhibition of proliferation we used serum-starved melanoma 
cells and monitored migration and invasion after 20 and 24 hours, respectively. As 
shown in Figure 4A, HER3 knock-down efficiently blocked melanoma cell migration in 
all three cell lines. In invasion experiments Colo 829 and Mel Gerlach cells were 
markedly inhibited upon HER3 suppression (Fig. 4B) while MM-358 cells did not 
invade the matrix even in untransfected controls (data not shown). These results 
establish HER3 as a potent mediator of melanoma cell migration and invasion. 
We next asked the question whether HER3 downregulation can induce melanoma 
cell death. However, in contrast to previously published data in lung cancer cells 
which undergo apoptosis in the absence of HER3 (15), suppression of HER3 did not 
induce major apoptosis in melanoma cells (Suppl.-Fig. 4). Nevertheless we reasoned 
that inhibition of HER3 might synergize with chemotherapy in the induction of 
apoptosis in melanoma cells. Indeed, we found that dacarbazine-induced apoptosis 
was significantly increased in HER3 knock-down melanoma cells (Fig. 4C and 
Suppl.-Fig. 1C). These results suggest that a combination therapy with HER3 and 
dacarbazine-like drugs might be useful for the treatment of malignant melanoma.  
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Anti-HER3 monoclonal antibodies block heregulin-induced HER3 activation 
and melanoma cell proliferation, migration and invasion 
We have shown above that HER3 is frequently overexpressed in primary melanoma 
and melanoma metastases and that high HER3 levels confer poor prognosis for 
melanoma patients. In addition, the RNA interference experiments suggest that 
HER3 may be a potential target for melanoma therapy. To test this hypothesis in vitro 
we treated Colo 829, MM-358, Mel Gerlach and Mel Juso melanoma cells with anti-
HER3 monoclonal antibodies. Remarkably, heregulin-induced activation of HER3 
and its association with the PI3-K subunit p85 was completely abrogated in antibody-
treated cells when compared to controls (Fig. 5A). In addition, anti-HER3 monoclonal 
antibodies seem to cause receptor degradation or internalization similar to previously 
obtained results in breast cancer cells (19). Importantly, anti-HER3 monoclonal 
antibodies are able to block heregulin-induced proliferation, migration and invasion of 
human melanoma cell lines (Fig. 5B, 5C, 5D and Suppl.-Fig. 2C) indicating that such 
antibodies may be effective anti-melanoma therapeutics. Importantly, in Mel Juso 
melanoma cells, HER2 inhibition by a specific monoclonal antibody had no effect on 
tumor cell invasion demonstrating that inhibition of HER3 is sufficient to block 
melanoma invasivity (Suppl.-Fig. 2C). 
Taken together, these results suggest that targeting HER3 may be a promising new 
opportunity for melanoma therapy. 
 
Discussion  
The discovery of animal oncogenes that are derived from genes encoding receptor 
tyrosine kinases has led over the past twenty years to the development of several 
targeted therapeutics with the HER2 monoclonal antibody Trastuzumab being the 
first in clinical application for the treatment of metastatic breast carcinoma with HER2 
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gene amplification. However, in spite of further advances in the development of side-
effect-poor therapies for major malignancies such as breast cancer, there is still a 
great unmet need for better, more effective therapies for other cancer types. 
Melanoma is a highly aggressive skin cancer and current therapies only show limited 
efficacy in patients with late stage disease (4, 30). So far it is known that the Ras-Raf-
MAPK and the PI3K-AKT pathways are frequently activated in malignant melanoma 
and that this contributes to tumor progression (30, 31). However, the role of receptor 
tyrosine kinases in melanoma development remains poorly characterized.  
HER3 is highly expressed in many human tumor types and has been associated in 
some cases with poor prognosis (8 - 10). Moreover, recent studies suggest that 
breast tumors exposed to EGFR or HER2 targeted therapies escape this inhibition by 
persistent activation of HER3 and the PI3K-AKT pathway (20 - 22) suggesting that 
agents targeting HER3 could provide a novel and promising approach towards the 
treatment of some cancers. We have recently shown that HER3 is frequently 
expressed in human melanoma cell lines (32) and macro-array analysis revealed that 
HER3 is the most prominently expressed HER-family receptor in these cell lines (P. 
Knyazev, unpublished data). Interestingly, HER3 and HER2 have been described to 
be expressed in human melanoma cell lines and both receptors were implicated in 
the control of melanoma cell growth (33). In the present study we show HER3 
expression in primary melanoma and its significant association with tumor cell 
proliferation. Furthermore, we demonstrate frequent and high HER3 expression in 
melanoma metastases, suggesting that HER3 may be involved in disease 
progression. In addition, high levels of HER3 significantly correlated with decreased 
life expectancy of patients establishing HER3 as a novel prognostic marker for 
melanoma. Importantly, HER3 expression is undetectable in primary melanocytes 
suggesting that HER3 overexpression specifically occurs during melanoma 
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development. The mechanism of HER3 overexpression appears to be caused by 
increased gene transcription since Southern blot analysis of 54 human melanoma 
cell lines did not reveal HER3 gene amplification (data not shown). So far, HER3 
gene amplifications could only be detected in non-small cell lung and breast cancer 
as well as in synovial sarcomas (34, 35, 36) whereas no amplification was reported 
for pancreatic, stomach, head and neck and brain tumors (37, 38, 39, 40). To 
specifically address the role of HER3 in melanoma development and progression, we 
analyzed human melanoma cell lines upon siRNA interference with HER3 
expression. Reduction of HER3 expression resulted in reduced cell proliferation, 
migration and invasion. On the molecular level, suppression of HER3 led to 
increased p27 protein levels and reduced Rb phosphorylation which seems to be the 
cause for the observed growth inhibition. Interestingly, HER3 can inhibit heregulin-
induced cell proliferation which may be due to an impaired AKT activity. In this 
context it is important to note that AKT is known to modulate the cellular localization 
of p27 thereby promoting cell cycle progression (41, 42, 43, 44); however, in 
melanoma cells p27 seems to be regulated by an AKT-independent pathway since 
p27 upregulation could also be seen in unstimulated HER3 knock-down cells. 
Interestingly, p27 proteolysis can be regulated by oncogenic signaling through the 
EGFR and HER2 which can be reversed by targeted inhibition of both receptors (45). 
It will be the topic of further studies to elucidate the mechanism of HER3-mediated 
p27 regulation in the control of human melanoma cell proliferation which may be 
similar to EGFR and HER2-mediated p27 regulation. Notably, HER3 ablation did not 
affect the ERK1/2 and mTOR kinases suggesting that inhibition of other downstream 
pathways seems to be sufficient to block melanoma cell proliferation, migration and 
invasion. Interestingly, mTOR phosphorylation at serine 2448 is known to be 
mediated by the PI3K-AKT pathway; however, inhibition of AKT in heregulin-
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stimulated cells did not result in downregulation of phospho-mTOR. In fact, mTOR 
seems to be constitutively activated as shown in unstimulated melanoma cells (Fig. 
3C). A possible explanation for this observation is that mTOR might be either 
activated through yet unknown mutations or directly modulated by the Ras-related 
GTPase Rheb as described recently (46, 47, 48).  
Furthermore, HER3 suppression led to a marked decrease in melanoma cell 
migration and invasion. It will be of importance to elucidate the exact role of HER3 in 
these processes and to identify factors which mediate HER3 responses during 
melanoma metastasis (e.g.: matrix-metallo proteinases). 
Interestingly, HER3 knock-down in lung cancer cells did lead to a significant increase 
in apoptosis (15). However, interference with HER3 function was not sufficient to 
induce major apoptosis of melanoma cells. Based on these results we tested whether 
a combination of HER3 downregulation with chemotherapeutic drug treatment would 
increase cell death. To date, dacarbazine is the only FDA-approved drug for the 
treatment of advanced melanoma with a tumor response rate of about 15-20% (4). 
Indeed, HER3 knock-down cells were highly sensitive to dacarbazine-induced 
apoptosis suggesting that a combination with agents interfering with HER3 might 
prove effective in the treatment of malignant melanoma. 
To further analyze whether HER3 may qualify as a novel target in melanoma therapy, 
we treated human melanoma cells lines with anti-HER3 monoclonal antibodies. We 
found that such antibodies can inhibit heregulin-induced HER3 phosphorylation 
leading to receptor internalization or degradation. Furthermore, we show that binding 
of p85, the regulatory subunit of PI3K, to HER3 is abrogated upon antibody-
incubation demonstrating that signaling via the PI3K/AKT signaling pathway is 
inhibited in these cells. Importantly, melanoma cell proliferation, migration and 
invasion are significantly reduced in antibody-treated cells when compared to 
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controls. These data demonstrate that anti-HER3 antibodies can inhibit HER3 
signaling most likely through the PI3K-AKT pathway in melanoma cell lines and 
thereby seem to block melanoma cell functions.  Importantly, we could show in Mel 
Juso melanoma cells that a monoclonal antibody specific for HER2 did not affect 
melanoma cell invasion suggesting that inhibition of HER3 alone is sufficient to block 
melanoma invasiveness (Suppl. Fig. 2C).  It will be essential in the future to test the 
efficacy of anti-HER3 blocking antibodies on melanoma development and metastasis 
in preclinical animal models in order to further validate HER3 as a possible target for 
melanoma therapy.  
Taken together, our results establish HER3 as a potential target for melanoma 
therapy development and interference with its function may offer a new and 
promising approach to improve clinical patient outcome. 
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Figure legends 
Fig. 1 HER3 expression in primary melanoma and metastases. 
Immunohistochemical staining of HER3 in primary melanoma and metastases.  
A Low HER3 expression (20x), B Moderate HER3 expression (40x) and C High 
HER3 expression (40x) in primary melanoma. HER3 immunoreactivity is accentuated 
at the cell membrane (black arrows). D High HER3 expression in melanoma 
metastases (40x). E HER3 expression frequencies in primary melanoma and 
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metastases. F Absence of HER3 expression in primary melanocytes. HER3 
expressing and non-expressing melanoma cell lines served as positive and negative 
controls, respectively. Tubulin served as a loading control. 
 
Fig. 2 HER3 protein expression confers poor prognosis in melanoma patients. 
A HER3 expression increases during melanoma progression. 20 primary tumors with 
matching melanoma metastases where evaluated based on their GIS score for 
HER3. B Kaplan-Meier analysis of tumor-specific survival according to HER3 
expression levels (p = 0,014). 
 
Fig. 3 HER3 knock-down inhibits melanoma cell proliferation  
A HER3 knock-down in Colo 829 and MM-358 melanoma cells. Western blots are 
shown for HER3 and Tubulin. B HER3 knock-down inhibits the proliferation of Colo 
829 and MM-358 melanoma cells. The growth curves were done as described in 
Material and Methods. The data are shown as mean ± SDM. Western blots for p27, 
p-Rb and Cyclin B1 are shown. Tubulin served as a loading control. C HER3 knock-
down impairs AKT activity upon heregulin ß1 stimulation in Colo 829 and MM-358 
melanoma cells. Western blots are shown for HER3, p-AKT, p27, p-ERK1/2 and p-
mTOR. ß-actin served as a loading control. 
 
Fig. 4 HER3 knock-down inhibits melanoma cell migration and invasion and 
induces apoptosis in response to chemotherapeutic drugs.  A HER3 knock-
down inhibits the migration of Colo 829, MM-358 and Mel Gerlach melanoma cells. 
For quantification, pictures of migrated cells were taken on a Zeiss Axiovert 300 
microscope and cells were counted in at least 10 random fields. The values for 
control cells were set to 100% and results are shown relative to controls. The data 
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are shown as mean ± SDM. B HER3 knock-down inhibits the invasion of Colo 829 
and Mel Gerlach melanoma cells. Quantification of invaded cells was done as 
described in A. C Induction of apoptosis in Colo 829 and MM-358 HER3 knock-down 
cells upon treatment with increasing amounts (10µM and 20µM) of dacarbazine. Data 
are shown as mean ± SDM. 
 
Fig. 5 An anti-HER3 monoclonal antibody (cl. 105.5) inhibits HER3 activation 
and blocks melanoma cell proliferation, migration and invasion. A Anti-HER3 
antibody treatment blocks heregulin-induced HER3 activation, its association with 
p85 and leads to receptor internalization or degradation. Colo 829, MM-358 and Mel 
Gerlach melanoma cells were serum-starved, incubated with 10µg/ml HER3 blocking 
antibody (cl. 105.5) or an isotype control antibody, stimulated with heregulin ß1, lysed 
and equal amounts of protein was subjected to Immunoprecipitations using a specific 
HER3 antibody. Western blots for p-HER3 (Y1289), HER3 and p85 are shown. B An 
anti-HER3 antibody (cl.105.5) inhibits heregulin-induced melanoma cell proliferation 
in vitro. Cell proliferation was measured by a MTT assay as described in Material and 
Methods.  MDA-MB 468 breast cancer cells served as a positive control as described 
previously (19). C An anti-HER3 antibody (cl.105.5) blocks melanoma cell migration 
in vitro. The cells were either incubated with 10µg/ml anti-HER3 antibody or an 
isotype control antibody. The migration assay was done in a modified boyden 
chamber. Conditioned NIH3T3 medium containing 100ng/ml heregulin ß1 was used 
as a chemo attractant. The quantification was done as described in Figure 4. The 
data are shown as mean ± SDM. D An anti-HER3 antibody (cl. 105.5) blocks 
melanoma cell invasion in vitro. The assay was done as in B using growth factor-
reduced matrigel in a modified boyden chamber.  
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  Table 1. Multivariate analysis of factors possibly influencing overall survival  
                (forward LR method) 
       
Variable Characteristics Hazard ratio (95%CI) p    
 
Age 0 ≤ 60 years ─ NS    
  
1 > 60 years 
      
Sex 0 = male ─ NS    
  
1 = female 
      
Tumor thickness 0 ≤ 2mm ─ NS    
  
1 > 2mm 
      
HER-3  0 low 2.6 (1.04-6.6) 0.041a    
  1 high      
Metastases during follow 
up 0 no metastases 22.2 (5.2-95.5) 0.000    
  1 metastases      
   
  a Bold type representing data with p < 0,05.      
     Abbreviations: NS, not significant; HR, hazard ratio; 95% CI, 95% confidence interval 
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